STAT3 and amyloidosis: When combined with results from the in vitro study by Liu and colleagues [62], our in vivo results suggest one mechanism by which STAT3 inhibition attenuates amyloid pathogenesis and its associated neurovascular deficits is by attenuating APP processing through inhibition of BACE1 activity.